Free Trial
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free RGNX Stock Alerts

REGENXBIO (RGNX) Financials

REGENXBIO logo
$5.73 -0.51 (-8.11%)
As of 03:56 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for REGENXBIO

Annual Income Statements for REGENXBIO

This table shows REGENXBIO's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -280 -263 -227
Consolidated Net Income / (Loss)		 -280 -263 -227
Net Income / (Loss) Continuing Operations		 -280 -263 -227
Total Pre-Tax Income 		-280 -264 -227
Total Operating Income		 -263 -268 -233
Total Gross Profit		 58 53 55
Total Revenue		 113 90 83
Operating Revenue		 113 90 83
Total Cost of Revenue		 55 37 29
Operating Cost of Revenue		 55 37 34
Other Cost of Revenue		 0.00 0.00 -5.00
Total Operating Expenses		 321 321 288
Selling, General & Admin Expense		 85 88 77
Research & Development Expense		 242 232 209
Other Operating Expenses / (Income)		 -6.68 0.40 0.87
Impairment Charge		 0.00 0.00 2.10
Total Other Income / (Expense), net		 -18 4.48 6.24
Interest Expense		 23 6.86 13
Interest & Investment Income		 5.38 11 19
Other Income / (Expense), net		 0.34 0.03 0.17
Income Tax Expense		 -0.08 -0.15 0.00
Basic Earnings per Share		 ($6.50) ($6.02) ($4.59)
Weighted Average Basic Shares Outstanding		 43.15M 43.73M 49.51M
Diluted Earnings per Share		 ($6.50) ($6.02) ($4.59)
Weighted Average Diluted Shares Outstanding		 43.15M 43.73M 49.51M
Weighted Average Basic & Diluted Shares Outstanding		 43.46M 44.43M 50.09M

Quarterly Income Statements for REGENXBIO

This table shows REGENXBIO's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -75 -60 -67 -72 -62 -63 -63 -53 -60 -51
Consolidated Net Income / (Loss)		 -75 -60 -67 -72 -62 -63 -63 -53 -60 -51
Net Income / (Loss) Continuing Operations		 -75 -60 -67 -72 -62 -62 -63 -53 -60 -52
Total Pre-Tax Income 		-75 -60 -67 -72 -62 -63 -63 -53 -60 -51
Total Operating Income		 -71 -58 -66 -73 -65 -64 -64 -56 -62 -51
Total Gross Profit		 13 19 15 11 17 11 11 12 12 20
Total Revenue		 27 31 19 20 29 22 16 22 24 21
Operating Revenue		 27 31 19 20 29 22 16 22 24 21
Total Cost of Revenue		 13 13 4.11 9.48 12 11 4.28 11 12 1.32
Operating Cost of Revenue		 13 13 4.11 9.48 12 11 4.28 11 12 6.32
Total Operating Expenses		 84 76 81 84 81 75 75 68 74 71
Selling, General & Admin Expense		 21 21 23 24 23 19 18 19 19 20
Research & Development Expense		 63 63 59 60 58 56 55 49 54 50
Other Operating Expenses / (Income)		 0.23 -7.38 0.03 0.03 0.22 0.12 -0.03 0.03 0.04 0.83
Total Other Income / (Expense), net		 -4.44 -2.21 -0.52 1.05 3.09 0.86 0.53 3.05 2.48 0.18
Interest Expense		 5.95 4.31 2.76 1.12 1.62 1.36 1.97 0.45 0.82 9.42
Interest & Investment Income		 1.50 2.03 2.17 2.13 4.66 2.37 2.47 3.47 3.28 9.52
Other Income / (Expense), net		 0.02 0.08 0.07 0.04 0.06 -0.14 0.04 0.03 0.03 0.08
Basic Earnings per Share		 ($1.75) ($1.38) ($1.53) ($1.66) ($1.41) ($1.42) ($1.38) ($1.05) ($1.17) ($0.99)
Weighted Average Basic Shares Outstanding		 43.25M 43.15M 43.45M 43.53M 43.95M 43.73M 45.73M 50.60M 50.80M 49.51M
Diluted Earnings per Share		 ($1.75) ($1.38) ($1.53) ($1.66) ($1.41) ($1.42) ($1.38) ($1.05) ($1.17) ($0.99)
Weighted Average Diluted Shares Outstanding		 43.25M 43.15M 43.45M 43.53M 43.95M 43.73M 45.73M 50.60M 50.80M 49.51M
Weighted Average Basic & Diluted Shares Outstanding		 43.29M 43.46M 43.47M 43.96M 43.99M 44.43M 49.26M 49.42M 49.55M 50.09M

Annual Cash Flow Statements for REGENXBIO

This table details how cash moves in and out of REGENXBIO's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -248 -62 23
Net Cash From Operating Activities		 -207 -218 -173
Net Cash From Continuing Operating Activities		 -207 -218 -173
Net Income / (Loss) Continuing Operations		 -280 -263 -227
Consolidated Net Income / (Loss)		 -280 -263 -227
Depreciation Expense		 13 17 16
Amortization Expense		 4.71 0.69 -4.14
Non-Cash Adjustments To Reconcile Net Income		 45 37 34
Changes in Operating Assets and Liabilities, net		 10 -10 7.42
Net Cash From Investing Activities		 -12 191 103
Net Cash From Continuing Investing Activities		 -12 191 103
Purchase of Property, Plant & Equipment		 -31 -9.96 -2.44
Purchase of Investments		 -185 -87 -190
Sale and/or Maturity of Investments		 204 287 296
Net Cash From Financing Activities		 -29 -35 93
Net Cash From Continuing Financing Activities		 -29 -35 93
Issuance of Common Equity		 1.74 6.70 132
Other Financing Activities, net		 -31 -42 -40
Cash Income Taxes Paid		 12 -0.14 -0.07

Quarterly Cash Flow Statements for REGENXBIO

This table details how cash moves in and out of REGENXBIO's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -2.83 -22 -27 -1.27 -16 -19 78 -55 -1.15 0.91
Net Cash From Operating Activities		 -50 -39 -81 -47 -49 -41 -55 -45 -41 -32
Net Cash From Continuing Operating Activities		 -50 -39 -81 -47 -49 -41 -55 -45 -41 -32
Net Income / (Loss) Continuing Operations		 -75 -60 -67 -72 -62 -63 -63 -53 -60 -51
Consolidated Net Income / (Loss)		 -75 -60 -67 -72 -62 -63 -63 -53 -60 -51
Depreciation Expense		 3.55 4.13 4.18 4.44 4.37 4.34 4.18 4.05 3.96 4.02
Amortization Expense		 1.13 0.90 0.68 0.38 -0.13 -0.24 -0.47 -1.24 -1.32 -1.12
Non-Cash Adjustments To Reconcile Net Income		 13 9.61 12 7.87 8.63 8.69 12 8.22 9.91 4.55
Changes in Operating Assets and Liabilities, net		 6.96 5.93 -31 12 -0.40 9.34 -7.64 -3.54 6.49 12
Net Cash From Investing Activities		 53 27 63 55 39 34 13 -0.27 50 40
Net Cash From Continuing Investing Activities		 53 27 63 55 39 34 13 -0.27 50 40
Purchase of Property, Plant & Equipment		 -5.05 -5.47 -4.82 -2.58 -1.44 -1.13 -0.56 -0.47 -0.33 -1.08
Purchase of Investments		 -15 -12 0.00 -50 -18 -19 -55 -83 -36 -16
Sale and/or Maturity of Investments		 73 44 68 108 58 54 69 83 87 58
Net Cash From Financing Activities		 -5.42 -8.92 -9.04 -9.16 -4.81 -12 121 -9.45 -11 -7.74
Net Cash From Continuing Financing Activities		 -5.42 -8.92 -9.04 -9.16 -4.81 -12 121 -9.45 -11 -7.74
Other Financing Activities, net		 -6.54 -8.92 -9.62 -9.16 -11 -12 -11 -9.20 -11 -7.74

Annual Balance Sheets for REGENXBIO

This table presents REGENXBIO's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 833 574 466
Total Current Assets		 416 335 278
Cash & Equivalents		 97 35 58
Short-Term Investments		 268 241 177
Accounts Receivable		 28 25 20
Prepaid Expenses		 14 15 9.07
Other Current Assets		 9.35 20 14
Plant, Property, & Equipment, net		 142 132 118
Total Noncurrent Assets		 276 107 70
Long-Term Investments		 201 39 10
Noncurrent Note & Lease Receivables		 1.50 0.70 0.47
Other Noncurrent Operating Assets		 72 65 58
Other Noncurrent Nonoperating Assets		 2.03 2.03 2.03
Total Liabilities & Shareholders' Equity		 833 574 466
Total Liabilities		 317 262 206
Total Current Liabilities		 130 130 103
Accounts Payable		 27 23 23
Accrued Expenses		 47 50 38
Current Deferred Revenue		 1.83 0.15 0.12
Other Current Liabilities		 55 58 42
Total Noncurrent Liabilities		 187 132 103
Other Noncurrent Operating Liabilities		 187 132 103
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 516 312 260
Total Preferred & Common Equity		 516 312 260
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 516 312 260
Common Stock		 973 1,021 1,193
Retained Earnings		 -442 -705 -932
Accumulated Other Comprehensive Income / (Loss)		 -15 -4.43 -0.74

Quarterly Balance Sheets for REGENXBIO

This table presents REGENXBIO's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 884 748 682 634 629 569 519
Total Current Assets		 437 389 379 366 395 347 313
Cash & Equivalents		 119 70 69 53 113 58 57
Short-Term Investments		 264 262 251 249 226 233 199
Accounts Receivable		 33 19 21 28 16 23 24
Prepaid Expenses		 15 16 15 13 14 10 11
Other Current Assets		 6.85 23 22 23 27 23 23
Plant, Property, & Equipment, net		 141 142 139 136 128 124 121
Total Noncurrent Assets		 306 217 165 132 106 99 85
Long-Term Investments		 235 142 95 63 42 37 23
Noncurrent Note & Lease Receivables		 1.80 1.30 1.14 1.08 0.52 0.46 0.40
Other Noncurrent Operating Assets		 68 72 66 66 62 59 60
Other Noncurrent Nonoperating Assets		 2.03 2.03 2.26 2.26 2.03 2.03 2.03
Total Liabilities & Shareholders' Equity		 884 748 682 634 629 569 519
Total Liabilities		 320 283 277 271 239 221 218
Total Current Liabilities		 124 112 118 127 110 98 103
Accounts Payable		 25 23 12 22 31 16 20
Accrued Expenses		 44 32 51 46 33 42 49
Current Deferred Revenue		 5.90 1.31 0.45 0.44 0.01 0.02 0.14
Other Current Liabilities		 48 56 55 59 46 39 34
Total Noncurrent Liabilities		 196 170 159 143 128 123 115
Other Noncurrent Operating Liabilities		 196 170 159 143 128 123 115
Total Equity & Noncontrolling Interests		 564 465 406 363 391 348 301
Total Preferred & Common Equity		 564 465 406 363 391 348 301
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 564 465 406 363 391 348 301
Common Stock		 964 985 996 1,013 1,162 1,172 1,183
Retained Earnings		 -382 -508 -580 -642 -768 -821 -881
Accumulated Other Comprehensive Income / (Loss)		 -18 -12 -10 -7.41 -3.23 -2.27 -0.58

Annual Metrics And Ratios for REGENXBIO

This table displays calculated financial ratios and metrics derived from REGENXBIO's official financial filings.

Metric 2022 2023 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - -
Revenue Growth		 -76.03% -19.94% -7.66%
EBITDA Growth		 -239.07% -2.12% 11.59%
EBIT Growth		 -263.37% -2.12% 13.03%
NOPAT Growth		 -227.09% -2.00% 12.97%
Net Income Growth		 -319.27% 6.00% 13.81%
EPS Growth		 -323.37% 7.38% 23.75%
Operating Cash Flow Growth		 -194.80% -5.26% 20.73%
Free Cash Flow Firm Growth		 -356.63% -6.48% 22.96%
Invested Capital Growth		 41.39% 91.35% 388.77%
Revenue Q/Q Growth		 -75.56% -9.19% -1.18%
EBITDA Q/Q Growth		 -286.16% -3.00% 4.97%
EBIT Q/Q Growth		 -328.50% -2.43% 5.19%
NOPAT Q/Q Growth		 -300.39% -2.34% 5.10%
Net Income Q/Q Growth		 -480.68% -1.13% 4.90%
EPS Q/Q Growth		 -477.91% -0.67% 8.57%
Operating Cash Flow Q/Q Growth		 -219.67% -0.64% 5.01%
Free Cash Flow Firm Q/Q Growth		 -398.86% 0.27% 8.19%
Invested Capital Q/Q Growth		 7.57% -19.99% -38.73%
Profitability Metrics		 - - -
Gross Margin		 51.61% 58.76% 65.72%
EBITDA Margin		 -217.27% -277.14% -265.34%
Operating Margin		 -233.20% -297.12% -280.03%
EBIT Margin		 -232.90% -297.09% -279.82%
Profit (Net Income) Margin		 -248.68% -291.99% -272.54%
Tax Burden Percent		 99.97% 99.94% 100.00%
Interest Burden Percent		 106.81% 98.34% 97.40%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% -3,918.02%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% -3,895.37%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 3,838.53%
Return on Equity (ROE)		 -43.78% -63.65% -79.49%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -1,415.24%
Operating Return on Assets (OROA)		 -26.97% -38.10% -44.84%
Return on Assets (ROA)		 -28.79% -37.45% -43.68%
Return on Common Equity (ROCE)		 -43.78% -63.65% -79.49%
Return on Equity Simple (ROE_SIMPLE)		 -54.31% -84.52% -87.46%
Net Operating Profit after Tax (NOPAT)		 -184 -188 -163
NOPAT Margin		 -163.24% -207.98% -196.02%
Net Nonoperating Expense Percent (NNEP)		 -13.58% -17.16% -22.65%
Return On Investment Capital (ROIC_SIMPLE)		 -35.65% -60.21% -62.91%
Cost of Revenue to Revenue		 48.39% 41.24% 34.28%
SG&A Expenses to Revenue		 75.65% 98.06% 91.95%
R&D to Revenue		 215.09% 257.38% 250.24%
Operating Expenses to Revenue		 284.82% 355.88% 345.75%
Earnings before Interest and Taxes (EBIT)		 -263 -268 -233
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -245 -250 -221
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.90 2.53 1.48
Price to Tangible Book Value (P/TBV)		 1.90 2.53 1.48
Price to Revenue (P/Rev)		 8.71 8.75 4.60
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 10.83
Enterprise Value to Revenue (EV/Rev)		 3.70 5.27 1.66
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00
Financial Leverage		 -1.11 -1.07 -0.99
Leverage Ratio		 1.52 1.70 1.82
Compound Leverage Factor		 1.62 1.67 1.77
Debt to Total Capital		 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00
Altman Z-Score		 0.62 -0.87 -2.71
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 3.19 2.57 2.69
Quick Ratio		 3.01 2.30 2.47
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 -220 -234 -181
Operating Cash Flow to CapEx		 -675.33% -2,192.84% -7,106.94%
Free Cash Flow to Firm to Interest Expense		 -9.46 -34.15 -14.26
Operating Cash Flow to Interest Expense		 -8.92 -31.83 -13.68
Operating Cash Flow Less CapEx to Interest Expense		 -10.24 -33.28 -13.87
Efficiency Ratios		 - - -
Asset Turnover		 0.12 0.13 0.16
Accounts Receivable Turnover		 3.73 3.41 3.68
Inventory Turnover		 0.00 0.00 0.00
Fixed Asset Turnover		 0.83 0.66 0.67
Accounts Payable Turnover		 2.83 1.49 1.25
Days Sales Outstanding (DSO)		 97.98 106.93 99.13
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 129.15 245.21 291.21
Cash Conversion Cycle (CCC)		 -31.17 -138.28 -192.08
Capital & Investment Metrics		 - - -
Invested Capital		 -51 -4.42 13
Invested Capital Turnover		 -1.63 -3.25 19.99
Increase / (Decrease) in Invested Capital		 36 47 17
Enterprise Value (EV)		 417 476 138
Market Capitalization		 982 790 383
Book Value per Share		 $11.92 $7.09 $5.24
Tangible Book Value per Share		 $11.92 $7.09 $5.24
Total Capital		 516 312 260
Total Debt		 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00
Net Debt		 -565 -314 -245
Capital Expenditures (CapEx)		 31 9.96 2.44
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -79 -71 -60
Debt-free Net Working Capital (DFNWC)		 286 205 175
Net Working Capital (NWC)		 286 205 175
Net Nonoperating Expense (NNE)		 96 76 64
Net Nonoperating Obligations (NNO)		 -567 -316 -247
Total Depreciation and Amortization (D&A)		 18 18 12
Debt-free, Cash-free Net Working Capital to Revenue		 -70.17% -78.19% -71.86%
Debt-free Net Working Capital to Revenue		 253.31% 226.83% 209.78%
Net Working Capital to Revenue		 253.31% 226.83% 209.78%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($6.50) ($6.02) ($4.59)
Adjusted Weighted Average Basic Shares Outstanding		 43.15M 43.73M 49.51M
Adjusted Diluted Earnings per Share		 ($6.50) ($6.02) ($4.59)
Adjusted Weighted Average Diluted Shares Outstanding		 43.15M 43.73M 49.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 43.46M 44.43M 50.09M
Normalized Net Operating Profit after Tax (NOPAT)		 -184 -188 -162
Normalized NOPAT Margin		 -163.24% -207.98% -194.26%
Pre Tax Income Margin		 -248.75% -292.15% -272.54%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 -11.29 -39.07 -18.42
NOPAT to Interest Expense		 -7.91 -27.35 -12.90
EBIT Less CapEx to Interest Expense		 -12.61 -40.52 -18.61
NOPAT Less CapEx to Interest Expense		 -9.23 -28.80 -13.10
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for REGENXBIO

This table displays calculated financial ratios and metrics derived from REGENXBIO's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -13.85% -91.75% -13.86% -38.81% 9.06% -29.13% -18.37% 11.60% -16.31% -4.50%
EBITDA Growth		 -25.43% -116.26% 9.13% -16.63% 8.56% -13.83% 1.82% 22.05% 2.07% 19.30%
EBIT Growth		 -24.11% -118.04% 7.48% -17.13% 8.62% -11.01% 3.42% 23.35% 4.39% 19.92%
NOPAT Growth		 -23.88% -113.48% 7.51% -16.91% 8.57% -10.61% 3.47% 23.35% 4.44% 19.62%
Net Income Growth		 -29.24% -120.38% 13.10% -5.69% 18.04% -4.93% 5.02% 26.47% 3.67% 18.61%
EPS Growth		 -27.74% -120.18% 14.53% -5.06% 19.43% -2.90% 9.80% 36.75% 17.02% 30.28%
Operating Cash Flow Growth		 -18.71% -111.53% -44.73% 23.36% 2.08% -3.53% 31.47% 3.86% 17.93% 22.41%
Free Cash Flow Firm Growth		 -143.05% -131.75% -48.32% 95.54% -42.81% -19.44% 44.05% -862.71% 29.95% 41.84%
Invested Capital Growth		 24.79% 41.39% 86.50% -136.68% 93.33% 91.35% 178.01% 260.70% 665.55% 388.77%
Revenue Q/Q Growth		 -18.80% 18.23% -38.94% 4.38% 44.74% -23.18% -29.67% 42.72% 8.53% -12.33%
EBITDA Q/Q Growth		 -13.38% 20.62% -16.26% -11.48% 11.12% 1.18% -0.27% 11.50% -11.67% 18.56%
EBIT Q/Q Growth		 -13.86% 18.77% -14.55% -10.56% 11.17% 1.33% 0.34% 12.25% -10.79% 17.35%
NOPAT Q/Q Growth		 -13.61% 18.68% -14.52% -10.51% 11.15% 1.63% 0.06% 12.25% -10.78% 17.25%
Net Income Q/Q Growth		 -10.71% 20.60% -11.25% -8.08% 14.15% -1.65% -0.70% 16.33% -12.47% 14.11%
EPS Q/Q Growth		 -10.76% 21.14% -10.87% -8.50% 15.06% -0.71% 2.82% 23.91% -11.43% 15.38%
Operating Cash Flow Q/Q Growth		 18.29% 21.97% -105.52% 41.52% -4.41% 17.50% -36.05% 17.96% 10.88% 22.01%
Free Cash Flow Firm Q/Q Growth		 58.31% -12.59% -47.81% 93.57% -1,235.18% 5.83% 30.77% -10.59% 2.85% 21.81%
Invested Capital Q/Q Growth		 -271.88% 7.57% 79.59% -13.12% 68.76% -19.99% 283.97% 133.04% 9.93% -38.73%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 50.61% 59.22% 78.51% 52.57% 57.16% 49.41% 72.58% 52.55% 48.81% 93.79%
EBITDA Margin		 -250.25% -168.02% -319.92% -341.66% -209.81% -269.89% -384.80% -238.62% -245.52% -228.05%
Operating Margin		 -267.97% -184.31% -345.68% -365.96% -224.67% -287.68% -408.80% -251.34% -256.55% -242.14%
EBIT Margin		 -267.91% -184.06% -345.32% -365.76% -224.47% -288.32% -408.56% -251.21% -256.45% -241.75%
Profit (Net Income) Margin		 -284.72% -191.21% -348.40% -360.72% -213.97% -283.12% -405.39% -237.67% -246.30% -241.28%
Tax Burden Percent		 100.00% 99.93% 100.00% 100.00% 100.00% 99.76% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 106.28% 103.96% 100.89% 98.62% 95.32% 98.43% 99.22% 94.61% 96.04% 99.81%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -2,442.39% 0.00% 0.00% 0.00% -4,380.38% -1,767.41% -3,387.87%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -2,438.28% 0.00% 0.00% 0.00% -4,376.70% -1,762.42% -3,382.46%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 2,390.42% 0.00% 0.00% 0.00% 4,335.18% 1,716.97% 3,333.11%
Return on Equity (ROE)		 14.36% -43.78% -46.81% -51.97% -56.22% -63.65% -60.80% -45.20% -50.44% -54.77%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,518.17% -1,081.77% -944.45% -1,415.24%
Operating Return on Assets (OROA)		 -146.71% -21.31% -42.70% -43.36% -29.40% -36.98% -51.46% -35.74% -37.52% -38.74%
Return on Assets (ROA)		 -155.92% -22.14% -43.09% -42.77% -28.02% -36.31% -51.06% -33.81% -36.03% -38.67%
Return on Common Equity (ROCE)		 14.36% -43.78% -46.81% -51.97% -56.22% -63.65% -60.80% -45.20% -50.44% -54.77%
Return on Equity Simple (ROE_SIMPLE)		 13.06% 0.00% -58.11% -67.55% -71.75% 0.00% -66.59% -69.22% -79.23% 0.00%
Net Operating Profit after Tax (NOPAT)		 -50 -40 -46 -51 -45 -45 -45 -39 -43 -36
NOPAT Margin		 -187.58% -129.01% -241.98% -256.17% -157.27% -201.38% -286.16% -175.94% -179.59% -169.50%
Net Nonoperating Expense Percent (NNEP)		 -4.46% -2.75% -3.28% -4.11% -3.33% -4.11% -4.34% -3.69% -4.99% -5.41%
Return On Investment Capital (ROIC_SIMPLE)		 - -7.83% - - - -14.35% - - - -13.85%
Cost of Revenue to Revenue		 49.39% 40.78% 21.49% 47.43% 42.84% 50.59% 27.42% 47.45% 51.19% 6.21%
SG&A Expenses to Revenue		 78.91% 67.67% 118.27% 118.63% 79.83% 85.89% 117.08% 84.57% 80.27% 94.52%
R&D to Revenue		 238.81% 199.41% 305.76% 299.77% 201.23% 250.67% 351.07% 219.19% 224.94% 237.48%
Operating Expenses to Revenue		 318.58% 243.53% 424.20% 418.53% 281.82% 337.09% 481.39% 303.89% 305.36% 335.93%
Earnings before Interest and Taxes (EBIT)		 -71 -58 -66 -73 -65 -64 -64 -56 -62 -51
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -66 -53 -61 -68 -61 -60 -60 -53 -59 -48
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 2.03 1.90 1.77 2.14 1.99 2.53 2.37 1.65 1.72 1.48
Price to Tangible Book Value (P/TBV)		 2.03 1.90 1.77 2.14 1.99 2.53 2.37 1.65 1.72 1.48
Price to Revenue (P/Rev)		 2.48 8.71 7.50 8.96 7.28 8.75 10.69 6.47 6.15 4.60
Price to Earnings (P/E)		 9.19 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 10.88% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 67.24 13.15 11.52 10.83
Enterprise Value to Revenue (EV/Rev)		 1.14 3.70 3.18 4.68 3.61 5.27 6.30 2.80 2.84 1.66
Enterprise Value to EBITDA (EV/EBITDA)		 3.99 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 4.57 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 5.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 3.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 7.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.13 -1.11 -1.08 -0.98 -1.06 -1.07 -1.00 -0.99 -0.97 -0.99
Leverage Ratio		 1.64 1.52 1.54 1.58 1.64 1.70 1.61 1.66 1.73 1.82
Compound Leverage Factor		 1.75 1.58 1.55 1.56 1.56 1.67 1.60 1.57 1.67 1.82
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 2.22 1.43 1.09 0.94 0.46 0.30 0.97 -0.10 -0.69 -1.42
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 3.53 3.19 3.46 3.21 2.87 2.57 3.59 3.53 3.05 2.69
Quick Ratio		 3.36 3.01 3.12 2.90 2.59 2.30 3.22 3.19 2.72 2.47
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -68 -76 -113 -7.27 -97 -91 -63 -70 -68 -53
Operating Cash Flow to CapEx		 -999.13% -719.78% -1,679.49% -1,836.32% -3,433.43% -3,619.89% -9,956.01% -9,598.52% -12,438.34% -2,930.86%
Free Cash Flow to Firm to Interest Expense		 -11.41 -17.74 -41.03 -6.49 -59.73 -67.02 -32.06 -155.78 -82.87 -5.64
Operating Cash Flow to Interest Expense		 -8.47 -9.14 -29.37 -42.25 -30.42 -29.90 -28.11 -101.33 -49.45 -3.36
Operating Cash Flow Less CapEx to Interest Expense		 -9.32 -10.40 -31.12 -44.55 -31.31 -30.73 -28.39 -102.39 -49.85 -3.47
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.55 0.12 0.12 0.12 0.13 0.13 0.13 0.14 0.15 0.16
Accounts Receivable Turnover		 11.74 3.73 4.78 3.29 3.28 3.41 5.00 4.03 3.27 3.68
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.51 0.83 0.79 0.70 0.72 0.66 0.64 0.68 0.66 0.67
Accounts Payable Turnover		 2.76 2.83 1.79 2.76 1.65 1.49 1.37 2.75 1.86 1.25
Days Sales Outstanding (DSO)		 31.09 97.98 76.37 110.81 111.28 106.93 73.00 90.57 111.77 99.13
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 132.09 129.15 203.97 132.37 221.63 245.21 266.73 132.77 196.22 291.21
Cash Conversion Cycle (CCC)		 -100.99 -31.17 -127.60 -21.56 -110.36 -138.28 -193.74 -42.21 -84.45 -192.08
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -55 -51 -10 -12 -3.68 -4.42 8.13 19 21 13
Invested Capital Turnover		 -7.17 -1.63 -2.50 9.53 -3.37 -3.25 -75.71 24.90 9.84 19.99
Increase / (Decrease) in Invested Capital		 18 36 67 -44 52 47 19 31 24 17
Enterprise Value (EV)		 526 417 348 454 359 476 546 249 240 138
Market Capitalization		 1,143 982 822 869 724 790 927 576 518 383
Book Value per Share		 $13.04 $11.92 $10.70 $9.34 $8.26 $7.09 $8.54 $7.07 $6.10 $5.24
Tangible Book Value per Share		 $13.04 $11.92 $10.70 $9.34 $8.26 $7.09 $8.54 $7.07 $6.10 $5.24
Total Capital		 564 516 465 406 363 312 391 348 301 260
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -617 -565 -474 -415 -365 -314 -381 -327 -279 -245
Capital Expenditures (CapEx)		 5.05 5.47 4.82 2.58 1.44 1.13 0.56 0.47 0.33 1.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -69 -79 -55 -59 -63 -71 -53 -42 -45 -60
Debt-free Net Working Capital (DFNWC)		 313 286 277 261 238 205 285 248 211 175
Net Working Capital (NWC)		 313 286 277 261 238 205 285 248 211 175
Net Nonoperating Expense (NNE)		 26 19 20 21 16 18 19 14 16 15
Net Nonoperating Obligations (NNO)		 -619 -567 -476 -418 -367 -316 -383 -329 -281 -247
Total Depreciation and Amortization (D&A)		 4.68 5.03 4.86 4.82 4.24 4.09 3.71 2.81 2.65 2.91
Debt-free, Cash-free Net Working Capital to Revenue		 -15.03% -70.17% -50.12% -61.01% -63.79% -78.19% -61.65% -47.11% -53.11% -71.86%
Debt-free Net Working Capital to Revenue		 67.89% 253.31% 252.52% 269.06% 239.99% 226.83% 328.90% 278.97% 249.83% 209.78%
Net Working Capital to Revenue		 67.89% 253.31% 252.52% 269.06% 239.99% 226.83% 328.90% 278.97% 249.83% 209.78%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.75) ($1.38) ($1.53) ($1.66) ($1.41) ($1.42) ($1.38) ($1.05) ($1.17) ($0.99)
Adjusted Weighted Average Basic Shares Outstanding		 43.25M 43.15M 43.45M 43.53M 43.95M 43.73M 45.73M 50.60M 50.80M 49.51M
Adjusted Diluted Earnings per Share		 ($1.75) ($1.38) ($1.53) ($1.66) ($1.41) ($1.42) ($1.38) ($1.05) ($1.17) ($0.99)
Adjusted Weighted Average Diluted Shares Outstanding		 43.25M 43.15M 43.45M 43.53M 43.95M 43.73M 45.73M 50.60M 50.80M 49.51M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 43.29M 43.46M 43.47M 43.96M 43.99M 44.43M 49.26M 49.42M 49.55M 50.09M
Normalized Net Operating Profit after Tax (NOPAT)		 -50 -40 -46 -51 -45 -45 -43 -39 -43 -36
Normalized NOPAT Margin		 -187.58% -129.01% -241.98% -256.17% -157.27% -201.38% -276.75% -175.94% -179.59% -169.50%
Pre Tax Income Margin		 -284.72% -191.35% -348.40% -360.72% -213.97% -283.80% -405.39% -237.67% -246.30% -241.28%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -11.93 -13.39 -23.99 -65.24 -39.97 -46.99 -32.35 -124.74 -75.67 -5.45
NOPAT to Interest Expense		 -8.35 -9.38 -16.81 -45.69 -28.00 -32.82 -22.66 -87.36 -52.99 -3.82
EBIT Less CapEx to Interest Expense		 -12.78 -14.66 -25.74 -67.54 -40.85 -47.81 -32.63 -125.80 -76.07 -5.56
NOPAT Less CapEx to Interest Expense		 -9.20 -10.65 -18.56 -47.99 -28.89 -33.65 -22.94 -88.42 -53.39 -3.93
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.10% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

REGENXBIO Inc. (RGNX) shows a mixed picture across the last four years of quarterly data. Here are the key points that investors should know, focusing on cash flows, profitability trends, and the balance sheet.

  • Very strong gross margin in Q4 2024: Total revenue was $21.214 million with gross profit of $19.896 million, implying a gross margin of about 93.8%. This suggests core product economics are favorable even as operating expenses produce losses.
  • Significant 2024 investing cash inflows: Net cash from continuing investing activities was about $50.3 million in Q3 2024 and $40.3 million in Q4 2024, driven by the sale/maturity of investments, boosting liquidity.
  • Equity financing boosted liquidity in early 2024: In Q1 2024, issuance of common equity totaled approximately $132.0 million, contributing to net cash from continuing financing activities of about $120.7 million.
  • Substantial liquidity buffers: 2024 balance sheets show sizable short-term investments (roughly $199–$233 million range) and cash in the tens of millions, providing a liquidity cushion for ongoing R&D and operations.
  • Robust asset base on the balance sheet: Total assets remained well over $500 million across 2024 quarters (e.g., around $519 million to $629 million), indicating scale to support ongoing activities.
  • Positive net financing activity in early 2024: The Q1 2024 period shows positive net cash from continuing financing activities, reflecting access to capital markets when needed.
  • Revenue fluctuates by quarter in 2024: Operating revenue moves within a relatively narrow band across Q1–Q4 2024, indicating some seasonality or timing effects in product sales.
  • High and persistent R&D spend: Research & development expenses run in the mid-to-high $40s–$50s millions per quarter in 2024, signaling ongoing pipeline investment that weighs on near-term profitability.
  • Balance sheet losses are cumulative: Retained earnings show substantial negative balances, reflecting years of net losses, which is typical for a development-stage biotech but important for evaluating future capital needs.
  • Bottom-line losses persist in 2024: Net income (and earnings per share) remained negative across all 2024 quarters (e.g., Q4 -$51.2M, Q3 -$59.6M, Q2 -$53.0M, Q1 -$63.3M), underscoring ongoing profitability challenges.
  • Operating cash flow negative throughout 2024: Cash from operating activities was negative in every quarter (roughly -$31.6M in Q4, -$40.5M in Q3, -$45.5M in Q2, -$55.5M in Q1), indicating ongoing cash burn from core operations.

Overall, RGNX demonstrates a strong gross margin and meaningful liquidity from investing and financing activities, which helps fund substantial R&D investment. However, ongoing operating losses and negative cash flow from operations suggest the company will likely need continued external capital or improved operating efficiency to reach sustainable profitability.

05/15/26 03:57 PM ETAI Generated. May Contain Errors.

REGENXBIO Financials - Frequently Asked Questions

According to the most recent income statement we have on file, REGENXBIO's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

REGENXBIO's net income appears to be on a downward trend, with a most recent value of -$227.10 million in 2024, falling from -$280.32 million in 2022. The previous period was -$263.49 million in 2023. See REGENXBIO's forecast for analyst expectations on what's next for the company.

REGENXBIO's total operating income in 2024 was -$233.35 million, based on the following breakdown:
  • Total Gross Profit: $54.76 million
  • Total Operating Expenses: $288.11 million

Over the last 2 years, REGENXBIO's total revenue changed from $112.72 million in 2022 to $83.33 million in 2024, a change of -26.1%.

REGENXBIO's total liabilities were at $206.34 million at the end of 2024, a 21.3% decrease from 2023, and a 34.9% decrease since 2022.

In the past 2 years, REGENXBIO's cash and equivalents has ranged from $34.52 million in 2023 to $96.95 million in 2022, and is currently $57.53 million as of their latest financial filing in 2024.

Over the last 2 years, REGENXBIO's book value per share changed from 11.92 in 2022 to 5.24 in 2024, a change of -56.0%.


Related Companies

Financial statements for NASDAQ:RGNX last updated on 4/6/2025 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Why this tiny stock may move before the SpaceX IPO drops
The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...
Behind the Markets | Sponsoredtc pixel
Satellite Images Spot Potential $10 Trillion Discovery
'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...
Altimetry | Sponsoredtc pixel
Revealed: The World’s First Trillion-Dollar Robot
Jensen Huang stood in Las Vegas and laid out Nvidia's vision for building the world's first trillion-dollar ro...
Weiss Ratings | Sponsoredtc pixel